Annual Chest Evaluation in Lymphoma

Initial Staging and Diagnosis

The European Society for Medical Oncology recommends chest X-ray and contrast-enhanced CT scan of neck, chest, and abdomen at diagnosis to assess for mediastinal involvement, which is a critical risk factor 3, 4, 5
PET-CT should be performed for accurate initial staging when available, as recommended by the European Society for Medical Oncology 6, 7
A large mediastinal mass is specifically defined as more than one-third of the maximum horizontal chest diameter and represents a key risk stratification factor, according to the European Society for Medical Oncology 3, 4

The European Society for Medical Oncology guidelines state that chest X-ray should be performed at 6, 12, and 24 months after treatment completion 1
After 24 months, chest imaging is performed only as clinically needed in patients suitable for further therapy, as recommended by the European Society for Medical Oncology 1
CT scan should be performed once to confirm remission status, but further regular CT scans are NOT recommended except for evaluation of residual disease, according to the European Society for Medical Oncology 1, 2
Annual routine chest imaging is not part of standard follow-up protocols, as stated by the European Society for Medical Oncology 1, 2, 6, 7

History and physical examination should be performed every 3 months for the first 6 months, every 6 months until year 4, then annually thereafter, as recommended by the European Society for Medical Oncology 2, 6, 7
Laboratory analysis (e.g., complete blood count, blood chemistry) follows the same schedule as clinical visits, according to the European Society for Medical Oncology 2, 6, 7
Imaging is reserved for evaluation of suspicious clinical symptoms rather than routine surveillance, as stated by the European Society for Medical Oncology 2

Female patients who received chest or axillary irradiation at age <40 years require annual mammography starting 8-10 years post-radiotherapy, and those treated at age <30 years need breast MRI in addition to mammography for secondary breast cancer screening, as recommended by the European Society for Medical Oncology 6, 7
This is for secondary malignancy screening, not lymphoma surveillance, according to the European Society for Medical Oncology 6, 7

Interim staging after completion of chemotherapy and prior to radiotherapy for early/intermediate stages should be performed, as recommended by the European Society for Medical Oncology 3, 4
Interim evaluation after 2-4 cycles for advanced stage disease should be performed, according to the European Society for Medical Oncology 3, 5
Final staging after treatment completion with physical examination, laboratory analyses, and contrast-enhanced CT should be performed, as recommended by the European Society for Medical Oncology 6, 7
PET-CT should be conducted if available for response assessment, according to the European Society for Medical Oncology 6, 7